PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS
    5.
    发明公开
    PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS 审中-公开
    嘧啶并二氮杂酮化合物和用于治疗疾病的方法

    公开(公告)号:EP2970317A4

    公开(公告)日:2016-11-02

    申请号:EP14764298

    申请日:2014-03-17

    摘要: The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.

    摘要翻译: 本发明涉及新的嘧啶并 - 二氮杂酮化合物,调节蛋白激酶,包括MPS1(TTK),ERK5(BMK1,MAPK7)LRKK2,EphA2的,马球激酶1,2,3,或4,ACK1,ACK 2,Abl的方法 ,DCAMKL1,ABL1,Abl的突变体,DCAMKL2,ARK5,BRK,MKNK2,FGFR4,TNK1,PLK1,ULK2,PLK4,PRKD1,PRKD2,PRKD3,ROS1,RPS6KA6,TAOK1,TAOK3,TNK2,BCR-ABL,GAK,CSRC, TPR-MET,Tie2的,MET,FGFR3,极光,Axl的,BMX,BTK,的c-kit,CHK2,FLT3,MST2,p70S6K的,PDGFR,PKB,PKC,Raf的,ROCK-H,RSK1,SGK,TrkA的,TrkB和 TrkC的,和在各种疾病,病症或病状的治疗中的用途测试化合物。

    PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS
    6.
    发明公开
    PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS 审中-公开
    嘧啶 - 二氮杂酮化合物和治疗疾病的方法

    公开(公告)号:EP2970317A2

    公开(公告)日:2016-01-20

    申请号:EP14764298.7

    申请日:2014-03-17

    摘要: The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.

    摘要翻译: 本发明涉及新的嘧啶并二氮杂酮化合物,调节蛋白激酶的方法,包括MPS1(TTK),ERK5(BMK1,MAPK7),LRKK2,EphA2,polo激酶1,2,3或4,Ack1,Ack2,Ab1 ,DCAMKL1,ABL1,Ab1突变体,DCAMKL2,ARK5,BRK,MKNK2,FGFR4,TNK1,PLK1,ULK2,PLK4,PRKD1,PRKD2,PRKD3,ROS1,RPS6KA6,TAOK1,TAOK3,TNK2,Bcr-Ab1,GAK,cSrc, TPR-Met,Tie2,MET,FGFR3,Aurora,Ax1,Bmx,BTK,c-kit,CHK2,Flt3,MST2,p70S6K,PDGFR,PKB,PKC,Raf,ROCK-H,Rsk1,SGK,TrkA, TrkC,以及这些化合物在治疗各种疾病,病症或病症中的用途。